Rewind Therapeutics
PrivateLast Round
Series A
Extension
Jan 25, 2023
Total Funding Raised
$21.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Rewind Therapeutics is a biotechnology company that develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from diseases such as multiple sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rewind Therapeutics Comparables
Compare Rewind Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Convelo Therapeutics | 87% | |
| Progentos Therapeutics | 86% | |
| Find Therapeutics | 86% |
Rewind Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 25, 2023 | ||||
| Grant | Aug 2, 2019 | ||||
| Series A | Jan 4, 2018 |
Rewind Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| M Ventures | Series A Extension |
| Centre for Drug Design and Discovery | Series A Extension, Series A |
| VLAIO | Grant |
| PMV | Series A Extension, Series A |
| Boehringer Ingelheim Venture Fund | Series A Extension, Series A |
| Sunstone Life Science Ventures | Series A Extension |
| M Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 67% MoM, reaching 1.6K.
- Aug 2, 2019
$3.2M grant received from VLAIO.
Rewind Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Rewind Therapeutics's valuation, stock price, and market status.
Is Rewind Therapeutics a public or private company?
Rewind Therapeutics is a private company.
What is the current stock price of Rewind Therapeutics?
Rewind Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Rewind Therapeutics worth (valuation)?
Valuation information for Rewind Therapeutics is not publicly available.
Can I buy Rewind Therapeutics stock?
Rewind Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Rewind Therapeutics's last funding round?
Rewind Therapeutics's most recent funding round was Series A Extension on January 25, 2023.
Who are the main investors in Rewind Therapeutics?
Key investors in Rewind Therapeutics include PMV, Boehringer Ingelheim Venture Fund, Sunstone Life Science Ventures, M Ventures.
Will Rewind Therapeutics IPO soon?
No public IPO plans have been announced for Rewind Therapeutics.
How can I track Rewind Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rewind Therapeutics's secondary market activity and sign up for updates.